NYSE:DGX - Quest Diagnostics Stock Price, News & Analysis

$101.60
-1.02 (-0.99 %)
(As of 08/25/2019 12:09 PM ET)
Today's Range
$101.23
Now: $101.60
$103.67
50-Day Range
$98.11
MA: $101.32
$103.37
52-Week Range
$78.95
Now: $101.60
$111.54
Volume1.61 million shs
Average Volume868,911 shs
Market Capitalization$13.68 billion
P/E Ratio16.10
Dividend Yield2.07%
Beta0.88
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP74834L10
Phone973-520-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.53 billion
Cash Flow$8.0571 per share
Book Value$40.91 per share

Profitability

Net Income$736 million

Miscellaneous

Employees46,000
Market Cap$13.68 billion
Next Earnings Date10/22/2019 (Estimated)
OptionableOptionable

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.


Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics announced a quarterly dividend on Thursday, August 15th. Investors of record on Friday, October 4th will be given a dividend of $0.53 per share on Monday, October 21st. This represents a $2.12 annualized dividend and a yield of 2.09%. The ex-dividend date is Thursday, October 3rd. View Quest Diagnostics' Dividend History.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) posted its quarterly earnings results on Tuesday, July, 23rd. The medical research company reported $1.73 EPS for the quarter, beating the consensus estimate of $1.69 by $0.04. The medical research company earned $1.95 billion during the quarter, compared to analyst estimates of $1.94 billion. Quest Diagnostics had a net margin of 9.64% and a return on equity of 15.05%. The business's revenue for the quarter was up 1.8% compared to the same quarter last year. During the same period last year, the firm earned $1.75 EPS. View Quest Diagnostics' Earnings History.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for Quest Diagnostics.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics updated its FY19 earnings guidance on Tuesday, July, 23rd. The company provided earnings per share guidance of >$6.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.46. The company issued revenue guidance of $7.6-7.75 billion, compared to the consensus revenue estimate of $7.69 billion.

What price target have analysts set for DGX?

18 equities research analysts have issued 12 month price objectives for Quest Diagnostics' stock. Their predictions range from $85.00 to $121.00. On average, they anticipate Quest Diagnostics' stock price to reach $104.6667 in the next year. This suggests a possible upside of 3.0% from the stock's current price. View Analyst Price Targets for Quest Diagnostics.

What is the consensus analysts' recommendation for Quest Diagnostics?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 3 sell ratings, 7 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Quest Diagnostics.

What are Wall Street analysts saying about Quest Diagnostics stock?

Here are some recent quotes from research analysts about Quest Diagnostics stock:
  • 1. Evercore ISI analysts commented, "We spent time on the west coast last week (LA + SF weather right now >>> Diagnostics (CFO and IR). Post solid 1H results after a reset in sentiment, numbers, and multiples last year, it is safe to say investor perception has recovered somewhat and the focus has shifted back towards the longer term path with the possibility of regulatory easing (particularly as organic volumes surprised last Q)." (8/8/2019)
  • 2. According to Zacks Investment Research, "Quest Diagnostics exited second-quarter 2019 with better-than-expected earnings as well as revenues. The company is refocusing on its diagnostic information services wing and disciplined capital deployment. Its acquisitions and collaborations with hospitals continue to act as key drivers. We are upbeat about Quest Diagnostics’ Preferred Network partnership with UnitedHealthcare. In the past three months, the company has outperformed its industry. On the flip side, the company is currently facing several reimbursement issues. Also, a rise in patient concession along with certain reserve adjustments caused a decline in revenue per requisition. Also, adjusted earnings declined on a year-over-year basis. This apart, escalating costs and a tough competitive landscape are concerns." (7/24/2019)
  • 3. Canaccord Genuity analysts commented, "We have written before that large labs (LH, DGX) and most of the rest of the non- specialized lab industry will face major challenges in 2019 and beyond. That said, we believe Quest is better positioned than LabCorp as Quest is a share gainer related to the UNH contract. DGX indicated that its UNH volumes build each week, and we expect DGX will drive 2-3 points of to offset the ~260bps headwind related to reimbursement. We think the 2019 bar is set appropriately and DGX likely can recover more in 2H/19. DGX is paying a 2.4% dividend yield. We maintain our BUY, trim our estimates and our PT to $97, which uses a 14.4x multiple on our ’20 Adj. EPS of $6.75. Q4/18 results. Adj. EPS of $1.36 (-3% Y/Y%) matched our/Street’s ~$1.36, while revs of $1,839M (-1.4% Y/Y) missed our/Street’s ~$1,878M (+0.7%). Rev./req." (2/18/2019)
  • 4. Barclays PLC analysts commented, "We were surprised there was another leg down in the quarter, though one silver lining is that volume growth of 3.4% appears improved – and the company noted that 2019 is off to a good start. $1.36 was modestly better than our forecast of $1.35. Additionally, Quest had an active 4Q18 of capital deployment, repurchasing $175mm of stock, $200mm towards acquisitions, and $68mm toward dividends. Ultimately, shares now trade at 13x our new 2019 EPS forecast of $6.40, and we believe sentiment is near a trough despite the potential for leverageable share gains in 2019. In our view, structural trends should be at the back of the national labs to consolidate testing share – and this is Quest’s time to shine." (2/15/2019)

Has Quest Diagnostics been receiving favorable news coverage?

Headlines about DGX stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Quest Diagnostics earned a news impact score of 2.5 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Quest Diagnostics.

Are investors shorting Quest Diagnostics?

Quest Diagnostics saw a decrease in short interest in July. As of July 31st, there was short interest totalling 3,988,700 shares, a decrease of 11.9% from the June 30th total of 4,526,800 shares. Based on an average daily volume of 929,200 shares, the days-to-cover ratio is presently 4.3 days. Currently, 3.0% of the shares of the company are sold short. View Quest Diagnostics' Current Options Chain.

Who are some of Quest Diagnostics' key competitors?

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Honeywell International (HON), Accenture (ACN), AutoZone (AZO) and United Rentals (URI).

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the folowing people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 62)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 57)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 56)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 56)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 44)

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.11%), BlackRock Inc. (9.19%), BlackRock Inc. (9.19%), Fiduciary Management Inc. WI (3.26%), Davis Selected Advisers (2.97%) and Victory Capital Management Inc. (2.37%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Everett Cunningham, Gail R Wilensky, J E Davis, Jeffrey M Leiden, Jon R Cohen, Mark Guinan, Michael E Prevoznik, Robert A Klug and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics.

Which institutional investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., BlackRock Inc., Russell Investments Group Ltd., Allianz Asset Management GmbH, Acadian Asset Management LLC, JPMorgan Chase & Co., AXA and WINTON GROUP Ltd. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Everett Cunningham, Gail R Wilensky, J E Davis, Mark Guinan, Michael E Prevoznik and Stephen H Rusckowski. View Insider Buying and Selling for Quest Diagnostics.

Which institutional investors are buying Quest Diagnostics stock?

DGX stock was bought by a variety of institutional investors in the last quarter, including Thoroughbred Financial Services LLC, Balyasny Asset Management LLC, Marshall Wace North America L.P., Nuveen Asset Management LLC, Davis Selected Advisers, Victory Capital Management Inc., Schroder Investment Management Group and Bank of America Corp DE. View Insider Buying and Selling for Quest Diagnostics.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $101.60.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $13.68 billion and generates $7.53 billion in revenue each year. The medical research company earns $736 million in net income (profit) each year or $6.31 on an earnings per share basis. Quest Diagnostics employs 46,000 workers across the globe.View Additional Information About Quest Diagnostics.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is http://www.questdiagnostics.com/.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]


MarketBeat Community Rating for Quest Diagnostics (NYSE DGX)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  410 (Vote Outperform)
Underperform Votes:  744 (Vote Underperform)
Total Votes:  1,154
MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel